Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Realty Income Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Realty Income Corp trades at $55.38 (market cap $52.03B). The key difference: Realty Income Corp is far larger — about 18.2× Dyne Therapeutics Inc. Common Stock's market cap, and Realty Income Corp pays a 5.92% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Realty Income Corp for 128 Days on average.
| DYN | O | |
|---|---|---|
Market Cap | $2.86B | $52.03B |
Volume | 3,341,579 | 16,838,213 |
Sector | Health | Real Estate |
52-Week High | $26.78 | $67.56 |
52-Week Low | $14.60 | $53.35 |
Typical Hold Time | 0 Days | 128 Days |
Enterprise Value | $2.18B | $82.66B |
Dividend Yield | — | 5.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Realty Income (O) trades at $55.17, up 0.86% on the day, but remains in a bearish technical trend with recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though valuation metrics appear elevated with a P/E of 40.14. Recent news highlights the stock's sensitivity to rising Treasury yields, with the 10-year at 5.26% creating headwinds for REIT valuations.
The outlook remains cautious with analyst consensus at Buy (38%) but technical indicators bearish. Key opportunities include the 6% dividend yield and 136 consecutive dividend increases, while risks center on interest rate sensitivity and debt levels approaching 40% of assets. The $64.16 price target suggests 16% upside if fundamentals overcome rate pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
